Table 1.
Numbers of colorectal cancer cases identified, excluded from, and included in the analysis.
| Country/region | Years of diagnosisa | Last follow-up date | Identified malignant casesb | Excluded cases |
Included cases (age group in years) | Cases included in stage-specific analysesd | ||
|---|---|---|---|---|---|---|---|---|
| Cases whose age at diagnosis was not in the age range of the population targeted by screening | Quality controlc | Cases with null survival | ||||||
| Belgiume | 2009-2016 | July 2018 | 66 051 | 31 779 | 0 | 26 | 34 246 (50-74) | 32 233 (94·1%) |
| Denmark | 2014-2018 | December 2018 | 22 579 | 8769 | 15 | 5 | 13 790 (50-74) | 11 167 (81·0%) |
| England | 2006-2015 | December 2018 | 335 991 | 202 870 | 169 | 1464 | 131 488 (60-74) | 48 241 (91·0%)f |
| France (5 regions) | - | - | 36 517 | 18 264 | 1 | 65 | 18 187 (50-74) | 17 569 (96·6%) |
| Burgundy | 2003-2016 | March 2019 | 10 295 | 5198 | 0 | 14 | 5083 (50-74) | 4949 (97·4%) |
| Calvados | 2004-2016 | March 2019 | 5160 | 2589 | 0 | 3 | 2568 (50-74) | 2458 (95·7%) |
| Doubs | 2008-2016 | March 2019 | 2773 | 1392 | 0 | 2 | 1379 (50-74) | 1336 (96·9%) |
| Finistere | 2004-2016 | April 2019 | 8469 | 4205 | 0 | 10 | 4254 (50-74) | 4112 (96·7%) |
| Isere | 2002-2016 | April 2019 | 9820 | 4880 | 1 | 36 | 4903 (50-74) | 4714 (96·1%) |
| Ireland | 2012-2016 | December 2018 | 12 848 | 9256 | 0 | 21 | 3571 (60-69) | 2857 (80·0%) |
| Italy (Turin) | 2003-2014 | December 2016g | 9523 | 7026 | 53 | 11 | 2433 (58-69) | -h |
| Netherlands | 2015i | February 2018 | 15 936 | 6469 | 0 | 6 | 9461 (60-75)j | 9324 (98·6%) |
| Slovenia | 2009-2015 | February 2019k | 10 513 | 5855 | 0 | 38 | 4620 (50-69) | 4387 (95·0%) |
| Spain (4 regions) | - | - | 25 081 | 14 695 | 11 | 37 | 10 338 (50-69) | 8594 (90·1%) |
| Basque Country | 2009-2015 | June 2019 | 14 974 | 8542 | 3 | 21 | 6413 (50-69) | 5237 (93·3%)l |
| Girona | 2013-2016 | December 2018 | 2280 | 1314 | 0 | 2 | 964 (50-69) | 870 (90·2%) |
| Murcia | 2006-2012 | January 2020 | 5866 | 3680 | 7 | 10 | 2169 (50-69) | 1970 (90·8%) |
| Tarragona | 2012-2014 | December 2016 | 1956 | 1159 | 1 | 4 | 792 (50-69) | 517 (65·3%) |
From the year screening was implemented up to the latest year with available data.
Malignant cases considered based on the international rules for reporting data on cancer incidence and survival – International Rules for Multiple primary cancers (ICD-O Third Edition). The exception was England which reports tumours with different morphology codes at the third digit level as multiple primary ones instead of using the IARC/IACR morphology groups.
Cases with negative survival, cases with missing, incomplete or inconsistent dates of diagnosis and follow-up/death, and cases with unknown data on sex and vital status were excluded.
Percentages shown in relation to the number of included cases.
In Belgium, screening was implemented on regional level. In Brussels and Wallonia, screening was introduced in 2009 and targeted individuals aged 50-74 years; in Flanders, it was introduced in 2013, was initially made available to those aged 66-74 years, and was gradually rolled out to include all individuals aged 56-74 years.
For England, data on stage were only available from 2012 onwards; therefore, patients diagnosed in 2006-2011 were not included in stage-specific analyses.
For Italy (Turin), the last follow-up date for disease-specific survival analyses was December 2015, as cause of death information was only available until that time point.
For Italy (Turin), data on stage were not available.
In the Netherlands, although the screening program started in 2014, data on mode of detection were only available for 2015.
In the Netherlands, although the screening program has been meanwhile extended to individuals aged 55-59, in 2015 only those whose age ranged from 60 to 75 years were invited.
For Slovenia, the last follow-up date for disease-specific survival analyses was December 2017, as cause of death information was only available until that time point.
For Spain (Basque Country), patients diagnosed in 2009 (>85% with unknown stage) were excluded from analyses of stage.